An observational study in Unresectable Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb. Recruiting at 2 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Bristol-Myers Squibb · Observational
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb — 3 open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Hepatocellular · Bristol-Myers Squibb.
Among the 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 21st registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →3 of the 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Australia, Chile and 11 more countries
Ages 18+
RayzeBio, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 9 · Phase 3 5
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 198 across the 19 interventional studies, 813 across the 2 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study looks at how a combination of two medicines, nivolumab and ipilimumab, is used to treat people with advanced liver cancer that cannot be removed by surgery. The study will follow adults receiving this treatment in routine medical care in Japan to understand how safe it is, how well it works, and how it is used in standard clinical practice.
Adults in Japan with Child-Pugh class A unresectable hepatocellular carcinoma initiating first-line nivolumab plus ipilimumab in routine clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who have not received prior systemic drug therapy for uHCC
Participants scheduled to initiate nivolumab plus ipilimumab combination therapy between March 1, 2026 and February 28, 2027
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with unresectable hepatocellular carcinoma receiving nivolumab plus ipilimumab as first-line systemic therapy in routine clinical practice in Japan.
Combination Product: Nivolumab plus ipilimumab
Drug pages: NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
According to product label
Number of participants with grade ≥3 immune-mediated liver injury (IMLI)
Number of participants who experience grade 3-5 immune-mediated liver injury (IMLI), defined as treatment-related hepatic adverse events assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time frame: Up to 2 years
Time to onset of immune-mediated liver injury (IMLI)
Time from first dose of nivolumab plus ipilimumab to first occurrence of immune-mediated liver injury (any grade).
Time frame: Up to 2 years
Time to resolution of immune-mediated liver injury (IMLI)
Time from onset of immune-mediated liver injury to resolution, defined as recovery, recovery with sequelae, or improvement per clinician assessment.
Time frame: Up to 2 years
Number of participants with immune-mediated liver injury (IMLI) who achieve resolution (recovered, recovering, or recovered with sequelae)
Time frame: Up to 2 years
Treatment prescribed to participants for immune-mediated liver injury (IMLI)
Time frame: Up to 2 years
Objective response rate (ORR)
Number of participants with complete response (CR) or partial response (PR) as best overall response among participants with baseline target lesions, assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Time frame: Up to 2 years
Best overall response (BOR)
Distribution of best overall response categorized as complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or not evaluable (NE) among participants with baseline target lesions per RECIST v1.1.
Time frame: Up to 2 years
Disease control rate (DCR
Number of participants with complete response (CR), partial response (PR), or stable disease (SD) as best overall response among participants with baseline target lesions per RECIST v1.1.
Time frame: Up to 2 years
Duration of nivolumab plus ipilimumab combination therapy
Time from first dose of nivolumab plus ipilimumab to treatment discontinuation.
Time frame: Up to 2 years
Number of nivolumab plus ipilimumab treatment cycles per participant
Total number of administered cycles of nivolumab plus ipilimumab given every 3 weeks, summarized per participant.
Time frame: Up to 2 years
Number of participants who discontinue treatment
Number of participants who discontinue nivolumab plus ipilimumab.
Time frame: Up to 2 years
Reasons for treatment discontinuation
Distribution of reasons, including disease progression, adverse events death, participant request, transfer, or other reasons as assessed by treating clinician.
Time frame: Up to 2 years
Number of participants with immune-mediated adverse events (IMAEs)
Number of participants experiencing IMAEs, defined as treatment-related adverse events with immune-mediated etiology, categorized by CTCAE v5.0 grade (1-5).
Time frame: Up to 2 years
Time to onset of immune-mediated adverse events (IMAEs)
Time from treatment initiation to onset of immune-mediated adverse events.
Time frame: Up to 2 years
Time to resolution of immune-mediated adverse events (IMAEs)
Time from onset of immune-mediated adverse events to resolution.
Time frame: Up to 2 years
Number of participants with immune-mediated adverse events (IMAEs) who achieve resolution (recovered, recovering, or recovered with sequelae)
Time frame: Up to 2 years
Treatment prescribed to participants for immune-mediated adverse events (IMAEs)
Time frame: Up to 2 years
Number of participants with of immune-mediated adverse events (IMAEs) leading to treatment discontinuation
Time frame: Up to 2 years
Number of participants with treatment-related adverse events (TRAEs)
Number of participants experiencing treatment-related adverse events categorized by preferred term and CTCAE v5.0 grade.
Time frame: Up to 2 years
Time to onset of treatment-related adverse events (TRAEs)
Time from treatment initiation to onset of immune-mediated adverse events.
Time frame: Up to 2 years
Time to resolution of treatment-related adverse events (TRAEs)
Time from onset of immune-mediated adverse events to resolution.
Time frame: Up to 2 years
Number of participants with treatment-related adverse events (TRAEs) who achieve resolution (recovered, recovering, or recovered with sequelae)
Time frame: Up to 2 years
Number of participants with treatment-related adverse events (TRAEs) leading to treatment discontinuation
Time frame: Up to 2 years
Duration of response (DOR)
Time from first documented complete response (CR) or partial response (PR) to disease progression per RECIST v1.1 or death from any cause, whichever occurs first
Time frame: Up to 2 years
Overall survival (OS
Time from first dose of nivolumab plus ipilimumab to death from any cause.
Time frame: Up to 2 years
Progression-free survival (PFS)
Time from first dose of nivolumab plus ipilimumab to first documented disease progression per RECIST v1.1 or death from any cause, whichever occurs first.
Time frame: Up to 2 years
Second progression-free survival (PFS2)
Time from first dose of nivolumab plus ipilimumab to progression after second-line therapy or death from any cause, whichever occurs first.
Time frame: Up to 2 years
Depth of response (DpR)
Maximum percentage reduction from baseline in the sum of diameters of target lesions among participants with measurable disease.
Time frame: Up to 2 years
Change from baseline in Child-Pugh score
Change from baseline in Child-Pugh score (range 5-15), including classification into Class A, B, or C.
Time frame: Up to 2 years
Change from baseline in albumin-bilirubin (ALBI) and modified ALBI (mALBI) grades based on laboratory values.
Time frame: Up to 2 years
Number of participants receiving subsequent therapy
Number of participants who receive any subsequent anticancer therapy after discontinuation of nivolumab plus ipilimumab
Time frame: Up to 2 years
Type of subsequent therapy received
Distribution of subsequent therapies received after discontinuation of nivolumab plus ipilimumab, including transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), radiofrequency ablation (RFA), surgery, radiation therapy, and systemic therapies.
Time frame: Up to 2 years
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Feb 2028, 23 months after the start.
Of 49 industry-sponsored observational studies under Carcinoma, Hepatocellular, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's planned 23 months is below that.
Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.